• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Laurus Labs receives USFDA approvals for two ANDAs under PEPFAR

expresspharmaMay 20, 2020

Tag: Laurus Labs , FDA , ANDA , TLE 400

Laurus Labs has received approval from USFDA under President’s Emergency Plan for AIDS Relief (PEPFAR) for two Abbreviated New Drug Application (ANDAs) TLE400 (Tenofovir/ Lamivudine/ Efavirenz – 300/300/400 mg) and TLE600 (Tenofovir/ Lamivudine/ Efavirenz – 300/300/600 mg) tablets.

Laurus Labs is one of the few players in the ARV segment to receive approval for TLE 400 tablets. TLE 400 is one of the most preferred regimens in the ARV first-line treatment. The Company already received WHO Pre-Qualification for TLE 400 (Tenofovir/ Lamivudine/ Efavirenz – 300/300/400 mg).

These approvals enable Laurus Labs to launch both the products in several LMIC markets.


Previous:ERT launches Virtual Visit solutions to keep clinical trials on track during COVID-19

Next:COVID-19 has made effective use of data in clinical development even more critical

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Laurus Labs receives USFDA approvals for two ANDAs under PEPFAR | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

EP/USP standard COENZYME Q10 303-98-0

EP/USP standard COENZYME Q10 303-98-0
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Adriacin HCL (FDA)

Adriacin HCL (FDA)
Clozapine (FDA)

Clozapine (FDA)
Pressure vessel and non - standard series

Pressure vessel and non - standard series
Plaster bandage

Plaster bandage
Marya GMP Standard Electronic Pharmaceutical Cleanroom Cargo Air Shower with High Efficiency System

Marya GMP Standard Electronic Pharmaceutical Cleanroom Cargo Air Shower with High Efficiency System
Bleomycin sulfate (FDA)

Bleomycin sulfate (FDA)
Ivermectin (FDA)

Ivermectin (FDA)
High standard Human Thrombin, Lyophilized for external use without preservatives

High standard Human Thrombin, Lyophilized for external use without preservatives

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service